other material
confidence high
sentiment positive
materiality 0.80
Verastem reports 45% ORR for avutometinib+defactinib in RAMP 201 LGSOC trial
Verastem, Inc.
- Combination achieved 45% ORR (13/29 evaluable) and tumor shrinkage in 86% of heavily pretreated LGSOC patients.
- KRAS mutant subgroup ORR 60% (9/15); KRAS wild type ORR 29% (4/14); median response time 5.5 months.
- Safety profile consistent with prior data; discontinuation rate 12%, mostly due to elevated CPK (4.9%).
- FDA Breakthrough Therapy Designation previously granted; company plans filing for accelerated approval.